Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study

Piercarlo Sarzi-Puttini, Emilio Filippucci, Silvano Adami, Pier Luigi Meroni, Alberto Batticciotto, Luca Idolazzi, Orazio De Lucia, Pablo Talavera, Thomas Kumke, Walter Grassi

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study'. Together they form a unique fingerprint.

Medicine & Life Sciences